Bone Resorption, Osteoclastogenesis and Adalimumab

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

March 31, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Adalimumab

Adalimumab 40 mg sub-cutaneously every two weeks

Trial Locations (1)

J1H 5N4

Centre de Recherche Clinique Ethienne Lebel, Fleurimont

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Université de Sherbrooke

OTHER